Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 04, 2023 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP Chief Patient & Ext Af Off | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
VERTEX PHARMACEUTICALS INC / MA
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,512 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 8,251 · Balance 66,512 F1: Restricted stock unit award that vests on 03/31/2030. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 882 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 882 |
| Common StockSEC Table I · non-derivative | IndirectHeld in Trust | 6,637 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,637 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/31/2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2026 Filed Jul 23, 2026 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,251 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000251 · wk-form4_1784837586.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,512 F1 · shares: Restricted stock unit award that vests on 03/31/2030. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,846 | $486.35 | $897,802.10 |
DisclosureSEC source: 0000875320-26-000118 · wk-form4_1772149844.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,570 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,518 | $485.11 | $736,396.98 |
DisclosureSEC source: 0000875320-26-000118 · wk-form4_1772149844.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,416 Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,026 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · derivative · entry 14 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,026 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,479 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · derivative · entry 13 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,479 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,237 | $471.43 | $1,997,448.91 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,934 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $471.43 (range $471.10 to $472.03). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,712 | $470.54 | $5,510,964.48 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,171 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $470.54 (range $470.10 to $471.08). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,241 | $469.61 | $3,400,446.01 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,883 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $469.61 (range $469.10 to $470.05). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 19,662 | $468.57 | $9,213,023.34 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,124 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $468.57 (range $468.10 to $469.09). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,263 | $467.75 | $4,800,518.25 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,786 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $467.75 (range $467.09 to $468.05). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,848 | $465.80 | $860,798.40 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,049 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $465.80 (range $465.54 to $466.49). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,730 | $465.05 | $1,269,586.50 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,897 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $465.05 (range $464.48 to $465.46). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 920 | $463.91 | $426,797.20 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,627 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F2 · price: Open market sales reported on this line occurred at a weighted average price of $463.91 (range $463.44 to $464.28). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 25,026 | $187.53 | $4,693,125.78 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 23,479 | $155.57 | $3,652,628.03 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,140 | $483.75 | $1,035,225.00 |
DisclosureSEC source: 0000875320-26-000096 · wk-form4_1771536296.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,042 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,789 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000096 · wk-form4_1771536296.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,182 F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,548 | $487.76 | $1,730,572.48 |
DisclosureSEC source: 0000875320-26-000074 · wk-form4_1771450792.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,393 Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 22:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,057 | $468.41 | $963,519.37 |
DisclosureSEC source: 0000875320-26-000050 · wk-form4_1770933974.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,941 Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,883 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000024 · wk-form4_1769463298.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,998 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000024 · wk-form4_1769463298.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,115 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,703 | $479.61 | $1,775,995.83 |
DisclosureSEC source: 0000875320-25-000133 · wk-form4_1740779155.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,490 Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,470 | $483.28 | $1,193,701.60 |
DisclosureSEC source: 0000875320-25-000113 · wk-form4_1740604411.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,193 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,139 | $463.46 | $991,340.94 |
DisclosureSEC source: 0000875320-25-000093 · wk-form4_1740000892.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,663 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,211 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000069 · wk-form4_1739567669.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,802 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,056 | $467.98 | $962,166.88 |
DisclosureSEC source: 0000875320-25-000046 · wk-form4_1739396879.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,591 Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,114 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000022 · wk-form4_1738878100.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,647 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,210 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000022 · wk-form4_1738878100.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,533 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftCommon Stock | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000172 · wk-form4_1717790851.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Indirect · Held in Trust Disclosed balance after: 0 Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 32 | $430.93 | $13,789.76 |
DisclosureSEC source: 0000875320-24-000154 · wk-form4_1715977634.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,325 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,004 | $425.70 | $1,278,802.80 |
DisclosureSEC source: 0000875320-24-000107 · wk-form4_1709071114.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,325 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,469 | $431.79 | $1,066,089.51 |
DisclosureSEC source: 0000875320-24-000107 · wk-form4_1709071114.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,329 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,191 | $421.77 | $1,345,868.07 |
DisclosureSEC source: 0000875320-24-000091 · wk-form4_1708723213.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,798 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,254 | $420.79 | $1,790,040.66 |
DisclosureSEC source: 0000875320-24-000078 · wk-form4_1708551484.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,989 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,623 | $420.58 | $1,103,181.34 |
DisclosureSEC source: 0000875320-24-000078 · wk-form4_1708551484.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,243 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,498 | $424.01 | $1,483,186.98 |
DisclosureSEC source: 0000875320-24-000078 · wk-form4_1708551484.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,866 Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,222 | $420.24 | $1,354,013.28 |
DisclosureSEC source: 0000875320-24-000053 · wk-form4_1707862481.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,364 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,022 | $422.74 | $854,780.28 |
DisclosureSEC source: 0000875320-24-000053 · wk-form4_1707862481.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,586 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,114 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000030 · wk-form4_1707428580.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,608 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2025. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000030 · wk-form4_1707428580.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,494 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000030 · wk-form4_1707428580.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,628 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 35 | $369.92 | $12,947.20 |
DisclosureSEC source: 0000875320-23-000041 · wk-form4_1700255780.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,814 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,031 | $350.00 | $3,510,850.00 |
DisclosureSEC source: 0000899243-23-018109 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,814 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:50 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001140361-23-010164 · form4.xml · derivative · entry 1 Sachdev Amit · CIK 0001406338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,468 | $289.12 | $713,548.16 |
DisclosureSEC source: 0001209191-23-013744 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,518 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,498 | $292.85 | $1,024,389.30 |
DisclosureSEC source: 0001209191-23-011699 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,986 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,657 | $298.26 | $1,388,996.82 |
DisclosureSEC source: 0001209191-23-009226 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,484 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,611 | $294.33 | $768,495.63 |
DisclosureSEC source: 0001209191-23-009226 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,141 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006973 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,752 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006973 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,886 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.